KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Quest Diagnostics (DGX) Shares Outstanding (2016 - 2026)

Quest Diagnostics' Shares Outstanding history spans 18 years, with the latest figure at $111.0 million for Q1 2026.

  • On a quarterly basis, Shares Outstanding fell 0.89% to $111.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $111.0 million, a 0.89% decrease, with the full-year FY2025 number at $162.0 million, up 45.95% from a year prior.
  • Shares Outstanding hit $111.0 million in Q1 2026 for Quest Diagnostics, down from $162.0 million in the prior quarter.
  • Over the last five years, Shares Outstanding for DGX hit a ceiling of $162.0 million in Q1 2022 and a floor of $111.0 million in Q4 2022.
  • Historically, Shares Outstanding has averaged $135.2 million across 5 years, with a median of $112.0 million in 2023.
  • The widest YoY moves for Shares Outstanding: up 45.95% in 2025, down 30.86% in 2025.
  • Tracing DGX's Shares Outstanding over 5 years: stood at $111.0 million in 2022, then changed by 0.0% to $111.0 million in 2023, then changed by 0.0% to $111.0 million in 2024, then surged by 45.95% to $162.0 million in 2025, then plummeted by 31.48% to $111.0 million in 2026.
  • Business Quant data shows Shares Outstanding for DGX at $111.0 million in Q1 2026, $162.0 million in Q4 2025, and $162.0 million in Q3 2025.